PA-GROVARA
19.5.2022 13:02:12 CEST | Business Wire | Press release
Grovara , the easy global wholesale experience, announces it has signed a lease agreement and become formally incorporated to do business in Dubai as part of a partnership with Dubai Global Connect (DGC) , a permanent wholesale market that facilitates business between international buyers and sellers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220519005017/en/
The partnership will integrate Grovara’s first-to-market digital global trading platform with DGC’s one-of-a-kind physical marketplace, providing unprecedented speed, reliability, and growth potential for DGC’s global wholesale buyers and sellers.
Grovara will leverage its international B2B online marketplace with DGC’s state-of-the-art showroom ecosystem for wholesale food, home furnishings, and fashion trade to supercharge CPG brands’ global distribution. Grovara’s digital platform streamlines and automates global wholesale trade, enabling buyers to find and manage suppliers and sellers while showcasing and selling goods online and managing fulfillment.
“The future of trade is digital, with a human touch. Our game-changing global marketplace will help bring Dubai Global Connect’s community of brands and buyers online,” says Grovara Co-Founder and CEO Abu Kamara. “Our technology is a turbo booster for international trade, and coupled with DGC’s state-of-the-art, bespoke physical showroom marketplace, Dubai is ready to be the launch pad.”
DGC’s facility will be one of the highlights of fast-growing Dubai South, the largest single urban master development in Dubai. Dubai South is being developed as an aviation and logistics ecosystem including a multi-modal transport infrastructure connecting air, land, and sea, and planned residential and commercial developments. DGC is located between Al Maktoum International Airport, which will be the world’s largest airport when construction is complete, and Jebel Ali Port, the Middle East’s busiest port.
With 2.5 billion people within a four-hour flight and 5 billion within an eight-hour flight, Dubai is globally recognized as an ideal place to live, work and play, while also offering transparent, business-friendly free-zone regulation across the country. The Dubai South Free Zone fosters ingenuity, offers ease of doing business, and provides comprehensive services that enable 100% foreign ownership and income and personal tax exemption.
Grovara will be the digital global wholesale option for those new businesses looking for buyers and sellers, with easy discovery, pricing, and purchasing that saves time and cost while delivering better performance via a curated marketplace. Sellers rely on Grovara’s automated export and operations document managers and achieve faster sales and brand valuations by selling to more customers.
“Our technology and in-country expertise will make it even easier for buyers and sellers from across the entire region to meet halfway in Dubai, where they’ll find all the support they need to grow,” says Grovara Sales Director Eugenia Schlitter.
DGC offers a number of physical spaces and services for brands and buyers, like showrooms, boutique offices, secure self-storage units with direct access to showrooms, and a smart service center offering a one-stop shop for a variety of business services. DGC is also planning a lavish auditorium, innovation hub, entrepreneurship center, and a year-round program of industry-specific programming.
“We are pleased to welcome Grovara to the Dubai Global Connect community here in Dubai,” says DGC’s Head of Business Development Paul Boots. “Grovara will be able to tap into DGC’s year-round physical showroom ecosystem and showcase some of the great brands available on their platform.
“Dubai is the natural gateway to the emerging markets, and the combination of Grovara and DGC will enable brands to expand their reach to a global buying audience, through Dubai. Partnerships such as these will further support DGC’s ambition to make Dubai a place of reference for the international B2B food trade, and we look forward to supporting them with the growth of their business.”
ABOUT GROVARA
Grovara enables an easy global wholesale experience as the first-to-market online marketplace supporting thousands of CPG products for export/import in more than 50 countries. With offices in Philadelphia, Mexico, and Dubai, Grovara facilitates global exporting and importing with a lightweight, tech-driven platform that provides automation and intelligence-based tools. Grovara leverages visibility, discovery, and an intuitive user experience to deliver easy transacting and management, creating a streamlined pathway to dynamic global growth potential. For more information or to join the curated ecosystem, please visit Grovara.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220519005017/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release
If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 15:00:00 CET | Press release
This framework agreement provides all entities subject to the French Public Procurement Code with simplified access to a support alternative enabling them to control their costs, preserve their freedom of technological choice and free themselves from vendor-imposed upgrade cycles Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMw
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 15:00:00 CET | Press release
New data in myeloproliferative neoplasms (MPNs) will include INCA033989, Incyte’s first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody, in first-line myelofibrosis (MF); and preclinical findings for Incyte’s next-generation mutCALR- and JAK2V617F-targeted compoundsUpdated results for INCA033989 in second-line MF and second-line essential thrombocythemia (ET) will build on previously presented datasetsLong-term Phase 1/2 data further characterize the potential of latarcibart (VGA039), an investigational Protein S-targeting antibody, as prophylaxis in adolescents and adults with von Willebrand disease (VWD)More than 30 abstracts will highlight progress across Incyte’s broader hematology portfolioIncyte will host an investor event and webcast on Saturday, December 12, 2026 from 7:30 – 9:00 p.m. CT (8:30 – 10:00 p.m. ET) Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstra
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 15:00:00 CET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 14:41:00 CET | Press release
Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom